Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $785.09, a high estimate of $1070.00, and a low estimate of $715.00. This current ...

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis ...

While counties are required to set aside at least 30 percent of their budgets to development projects, CoB documents also ...

The news came as RBC Capital analyst Luca Issi initiated coverage on Argenx with an outperform rating and 850 price target, saying that doctor checks point to accelerating uptake of Vyvgart, according ...

Step up in your career with a world-class executive MBA program crafted for mid to senior executives. Enrol today and lead with confidence.

As biotech firm Sarepta Therapeutics (NASD: SRPT) battles patient deaths, regulatory action, and a cratering stock price, its dealings with the Food and Drug Administration are being monitored closely ...